

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Data generated for the analysis, including the multiple sequence alignments, log files, example data to run scripts and to generate figures were deposited in the Zenodo database under accession code 10.5281/zenodo.13221957 and are also available on GitHub: https://github.com/ncbi/AF2_benchmark. The supporting data generated in this study are provided in the Supplementary Information and the Source Data file. The structural data used in this study were taken from the Protein Data Bank, details in supporting data (Supplementary Data 1) and the ones mentioned in the manuscript are listed below with their accession codes –

NMR structure of Sa1_V90T_8e6y (<https://doi.org/10.2210/pdb8e6y/pdb>), chain A, solution structure of PSD-1_2fs1 (<https://doi.org/10.2210/pdb2fs1/pdb>), chain A, Solution structure of V21C/V59C Lymphotactin/XCL1_2hdm (<https://doi.org/10.2210/pdb2hdm/pdb>), chain A, Crystal structure of human BCCIP beta (Native2)_7kys (<https://doi.org/10.2210/pdb7kys/pdb>) chain A, Crystal structure of human FAM46A-BCCIPa complex_8exf (<https://doi.org/10.2210/pdb8exf/pdb>) chain B, Crystal structure of the RfaH transcription factor_2oug (<https://doi.org/10.2210/pdb2oug/pdb>), chain C, Crystal structure of E.coli RNA polymerase elongation complex bound with RfaH_6c6s (<https://doi.org/10.2210/pdb6c6s/pdb>), chain D, Wild Type Crystal Structure of Full Length Circadian Clock Protein KaiB from Thermosynechococcus elongatus BP_2qke (<https://doi.org/10.2210/pdb2qke/pdb>), chain E, NMR structure of foldswitch-stabilized KaiB from Thermosynechococcus elongatus_5jyt (<https://doi.org/10.2210/pdb5jyt/pdb>) chain A, Crystal Structure of the Mad2 Dimer_3gmh_L (<https://doi.org/10.2210/pdb3gmh/pdb>), chain L and 2vfx (<https://doi.org/10.2210/pdb2vfx/pdb>) chain L. Source data are provided with this paper.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	N/A
Reporting on race, ethnicity, or other socially relevant groupings	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	all 92 fold-switching protein pairs, the NusG variants not in the PDB along with Sa1 and BCCIPa sequences were used for benchmarking
Data exclusions	Not relevant to this study
Replication	5 AlphaFold2 and AlphaFold3 structures were produced for each sequence of 92 fold-switching pairs, 50 predictions for the new PDBs and the NusG variants, 10 CD scans for variant 13, which showed the results to be reproducible.
Randomization	Not relevant to this study. We measured the CD spectrum of one protein. This does not require randomization.
Blinding	Not relevant to this study. We measured the CD spectrum of one protein. This does not require randomization.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

- | n/a | Included in the study |
|-------------------------------------|--|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Antibodies |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Eukaryotic cell lines |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology and archaeology |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Animals and other organisms |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Clinical data |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Dual use research of concern |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Plants |

Methods

- | n/a | Included in the study |
|-------------------------------------|---|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Flow cytometry |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging |